United Kingdom · Question · Written question
UIN 54517
Tixagevimab/cilgavimab
Introduced
22 September 2022
Last action
11 October 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
11 October 2022
Summary
To ask the Secretary of State for Health and Social Care, whether she plans to expand the availability of Evusheld as a prophylactic through clinical trials.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
22 September 2022
Written question
To ask the Secretary of State for Health and Social Care, whether she plans to expand the availability of Evusheld as a prophylactic through clinical trials.
Source: Commons
11 October 2022
Answer
Following engagement with AstraZeneca, we have encouraged the company to continue discussions with the Antivirals and Therapeutics Taskforce (ATTF) and the Chief Scientific Adviser on options for evaluating the clinical effectiveness of Evusheld. Clinical...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-09-22/54517
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1507578
- uk · wq-1507578 · source updated 11 October 2022